Monoclonal antibody therapy of chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1874-1881

  Mavromatis, Blanche ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; BL 22; DENILEUKIN DIFTITOX; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RADIOIMMUNOCONJUGATE DERIVATIVE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER ANTIBODY;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG SAFETY; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MONOTHERAPY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTOXINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; RADIOIMMUNOTHERAPY;

EID: 0038473993     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.113     Document Type: Review

References (92)

1. Rai KR, Peterson BL, Kolitz J, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
2. Saven A, Lemon RH, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
3. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 7:433-438, 1989
4. Ehrlich P: The Croonian Lecture: "On immunity with special reference to cell life." Proc R Soc 66:424-448, 1900
5. Bannerji R, Byrd JC: Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol 12:22-29, 2000
6. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
7. Dillman RO, Shawler DL, Dillman JB, et al: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881-891, 1984
8. Hertler AA, Schlossman DM, Borowitz MJ, et al: A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J Biol Response Mod 7:97-113, 1988
9. Zimmer AM, Kaplan EH, Kazikiewicz JM, et al: Pharmacokinetics of 1-131 T101 monoclonal antibody in patients with chronic lymphocytic leukemia. Antibody Immunoconjugates Radiopharm 1:291-303, 1988
10. Laurent G, Pris J, Parcel J-P, et al: Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 67:1680-1687, 1986
11. Capel PJA, Preijers FWMB, Allebes WA, et al: Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotype antibody. Neth J Med 28:112-118, 1985
12. Chatterjee M, Barcos M, Han T, et al: Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. Blood 76:1825-1829, 1990
13. Swisher EM, Shawler DL, Collins HA, et al: Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 77:1977-1982, 1991
14. Allebes WA, Preijers FWMB, Haanen C, et al: The development of non-responsiveness to immunotherapy with monoclonal anti-idiotypic antibodies in a patient with B-CLL. Br J Haematol 70:295-300, 1988
15. Dyer MJS, Hale G, Hayhoe FGJ, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431-1439, 1989
16. Hale G, Xia M-Q, Tighe HP, et al: The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118-127, 1990
17. Ginaldi L, De martinis M, Matutes E, et al: Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 22:185-191, 1998
18. Österborg A, Dyer MJS, Bunjes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567-1574, 1997
19. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
20. Bowen AL, Zomas A, Emmett E, et al: Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617-619, 1997
21. Rawstron AC, Davies FE, Evans P, et al: CAMPATH1H therapy for patients with refractory chronic lymphocytic leukemia (CLL). Blood 90:529a, 1997 (abstr 2356)
22. Stilgenbauer S, Scherer K, Kröber A, et al: Campath-1H in refractory B-CLL: Complete remission despite p53 gene mutation. Blood 98:771, 2001 (abstr 3211)
23. McCune SL, Gockerman JP, Moore JO, et al: Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 43:1007-1011, 2002
24. Österborg A, Passas AS, Anagnostopoulos A, et al: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151-153, 1996
25. Lundin J, Kimby E, Björkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002
26. Rai KR, Keating MJ, Coutré S, et al: Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM511 trial. Blood 100:802a, 2002 (abstr 3165)
27. Döhner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
28. Pawson R, Dyer MJS, Barge R, et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15:2667-2672, 1997
29. Dearden CE, Matutes E, Cazin B, et al: High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721-1726, 2001
30. Keating MJ, Cazin B, Coutré S, et al: Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20:205-213, 2002
31. Kennedy B, Rawstron A, Carter C, et al: CAMPATH-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245-2247, 2002
32. Rai KR, Byrd JC, Peterson B, et al: A phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901. Blood 100:205a, 2002 (abstr 772)
33. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
34. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
35. Maloney DG, Grillo-López AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20- monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
36. Nguyen DT, Amess JA, Doughty H, et al: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62:76-82, 1999
37. Piro LD, White CA, Grillo-Lopez AJ, et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655-661, 1999
38. Winkler U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999
39. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
40. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001
41. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
42. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
43. Hainsworth JD, Burris HA III, Morrissey LH, et al: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 95:3052-3056, 2000
44. Thomas DA, O'Brien S, Giles FJ, et al: Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98:364a, 2001 (abstr 1533)
45. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507-2513, 2003
46. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
47. Seipelt G, Bohme A, Koschmieder S, et al: Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evan's syndrome. Ann Hematol 80:170-173, 2001
48. Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). Blood 98:363a, 2001 (abstr 1530)
49. Byrd JC, Peterson B, Park K, et al: Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB 9712. Proc Am Soc Clin Oncol 20:280a, 2001 (abstr 1116)
50. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
51. Alas S, Emmanoulides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
52. Alas S, Bonavida B: Rituximab inactivates signal transducer and activator of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137-5144, 2001
53. Johnson TA, Press OW: Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 85:104-112, 2000
54. Schulz H, Klein SK, Rehwald U, et al: Phase H-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL). Blood 98:364a, 2001 (abstr 1534)
55. Garcia-Manero O, O'Brien S, Cortes J, et al: Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 98:633a, 2001 (abstr 2650)
56. Wierda W, O'Brien S, Albitar M, et al: Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98:771a, 2001 (abstr 3210)
57. Ghazal HH: Successful treatment of pure red cell aplasia (PRA) with rituxan in patients with CLL. Blood 98:219a, 2001 (abstr 914)
58. Hegde UP, Wilson WH, White T, et al: Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100:2260-2262, 2002
59. Nabhan C, Tallman MS, Riley MB, et al: Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 98:365a, 2001 (abstr 1536)
60. Faderl S, Thomas DA, O'Brien S, et al: Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies: An update of the M. D. Anderson experience. Blood 100:206a, 2002 (abstr 775)
61. Frankel AE, Patrick CL, Powell BL: Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL). Blood 98:289b, 2001 (abstr 4901)
62. Waters JS, Webb A, Cunningham D, et al: Phase I and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1809-1811, 2000
63. Smith M, Joshi I, Jin F: Combined therapy with antisense BCL-2 oligonucleolides (AS-BCL2-ODN) + alpha-CD20 monoclonal antibody in scid/human lymphoma xenografts. Blood 96:338a, 2000 (abstr 1458)
64. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471, 1999
65. Byrd JC, Waselenko JK, Maneatis T, et al: Rituximab therapy in hematologic malignancy patients with circulating tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791-795, 1999
66. Cheson BD, Frame JN, Vena D, et al: Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16:2313-2320, 1998
67. Leonard JP, Coleman M, Matthews JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL). Blood 100:358a, 2002 (abstr 1388)
68. Pathan N, Hariharan K, Hopkins M, et al: Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells. Blood 98:367a, 2001 (abstr 1545)
69. Link BK, Wang H, Byrd JC, et al: Phase I trial of humanized ID10 (Hu1D10) monoclonal antibody targeting class H molecules in patients with relapsed lymphoma. Proc Am Soc Clin Oncol 19:24a, 2000 (abstr 86)
70. Link BK, Kahl B, Czuczman M, et al: A phase 11 study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphomas. Blood 98:606a, 2001 (abstr 2540)
71. Hedge U, White T, Stetler-Stevenson M, et al: Phase I study of combination rituximab (CD20) and apolizomab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 100:358a, 2002 (abstr 1389)
72. König A, Menzel T, Lynen S, et al: Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11:258-265, 1997
73. Langmuir VK, Cobleigh MA, Herbst RS, et al: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 21:9a, 2002 (abstr 32)
74. Figg D, Fruger EA, Price DK: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 20:183-194, 2002
75. Karp JE, Gojo I, Gocke CD, et al: Timed sequential therapy (TST) of relapsed and refractory adult acute myelogenous leukemia (AML) with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. Blood 100:198a, 2002 (abstr 744)
76. Grossbard ML, Freedman AS, Ritz J, et al: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase 1 trial of daily bolus infusion. Blood 79:576-585, 1992
77. Grossbard ML, Lambert JM, Goldmacher VS, et al: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726-737, 1993
78. Multani PS, O'Day S, Nadler LM, et al: Phase II clinical trial of bolus infusion of anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 4:2599-2604, 1998
79. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247, 2001
80. LeMaistre CF, Meneghetti C, Rosenblum M, et al: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expression the IL-2 receptor. Blood 79:2547-2554, 1992
81. Fleming DR, Powell BL, Patrick CL, et al: Diphtheria fusion protein OhJTAK therapy of patients with fludarabine refractory chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 19:268a, 2002 (abstr 1071)
82. Dillman RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20:3545-3547, 2002
83. Cheson BD: Radioimmunotherapy of non-Hodgkin's lymphomas. Blood 101:391-398, 2003
84. Epstein AL, Marder RJ, Winter JN, et al: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830-840, 1987
85. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjugates Radiopharm 1:17-33, 1988
86. 131I-Lym-1. Cancer Res 50:1014s-1016s, 1990 (suppl)
87. Lewis JP, DeNardo GL, DeNardo SJ, et al: Impact of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia (CLL). Blood 76:295a, 1990 (abstr 1171)
88. DeNardo GJ, Lewis JP, DeNardo SJ, et al: Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73:1425-1432, 1994
89. Hu E, Epstein AL, Naeve GS, et al: A phase Ia clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7:155-166, 1989
90. Kaminski MS, Press OW, Lister TA, et al: Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): Overall clinical trial experience. Blood 94:88a, 1999 (abstr 386)
91. Rosenwald A, Alizadeh AA, Widhopf G, et al: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1647, 2001
92. Chen L, Widhopf G, Huynh L, et al: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609-4614, 2002